AXIM - AXIM Biotechnologies, Inc.
| Previous Close | 0.7400 |
| Open | 0.7400 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.7300 - 0.7400 |
| 52 Week Range | 0.4600 - 3.4900 |
| Volume | 14,568 |
| Avg. Volume | 88,703 |
| Market Cap | 45.564M |
| Beta (3Y Monthly) | -4.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.1080 |
| Earnings Date | May 1, 2018 - May 7, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire•12 days ago
AXIM® Biotechnologies Receives Seventh Private Label Gum Purchase Order Pushing Orders to Nearly $900,000 for Last Five Months
NEW YORK, July 11, 2019 -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development,.
- GlobeNewswire•14 days ago
AXIM® Biotechnologies Signs Licensing Agreement With Leading Gum Distributor to Expand Nutraceutical Division
NEW YORK, July 09, 2019 -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development,.
- PR Newswire•27 days ago
Medical Marijuana, Inc. Major Investment Company AXIM® Biotechnologies, Inc.'s Cannabinoid Oral Care Products Registered For Use In Clinical Trials Through Australian Healthcare Partner
NEW YORK , June 26, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA ) (the "Company"), the first-ever publicly traded cannabis company in the United States that launched the world's ...
- GlobeNewswire•28 days ago
AXIM® Biotechnologies Signs Supply Agreement to Register Cannabinoid Oral Care Products in Clinical Trials for Gingivitis and Gum Disease
NEW YORK, June 25, 2019 -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and development, today.
- GlobeNewswire•2 months ago
FOX Business Features Opinion Article Authored by AXIM Biotechnologies, Inc. CEO on Why Legal CBD is Good for Consumers and the Economy
AXIM® Biotechnologies, Inc. (AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today announced that it has garnered news coverage for an opinion article in top U.S. consumer publication FOX Business. The article was co-authored by John W. Huemoeller II, the Company’s CEO, and Dr. Stuart Titus, CEO of Medical Marijuana Inc., the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products.
- GlobeNewswire•2 months ago
AXIM® Biotechnologies, Inc. Signs Cannabinoid Product Supply Agreement with Healthcare Company for Clinical Trials on Treatment of Periodontitis
AXIM® Biotechnologies, Inc. (AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), a world leader in cannabinoid research and product development, today announced that it has signed a cannabinoid product supply agreement with Impression Healthcare Limited (“Impression”) for the supply of the Company’s toothpaste and mouthwash containing cannabidiol (CBD) for its clinical trial for the treatment of periodontitis.
- PR Newswire•2 months ago
Cannastocks2019 Investor Conference & Webinar Now Available for On-Demand Viewing
Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view presentations NEW YORK , May 17, 2019 /PRNewswire/ -- Virtual Investor Conferences, ...
- GlobeNewswire•2 months ago
AXIM® Biotechnologies Announces Additional Purchase Order for Nutraceutical Product With Leading Direct Selling Company
NEW YORK, May 15, 2019 -- AXIM® Biotechnologies, Inc. (OTC: AXIM) (“AXIM® Biotech”, “AXIM”, or the “Company”), a world leader in cannabinoid research and development, today.
- CNW Group•2 months ago
Cannastocks2019 Live-Stream Investor Conference & Webinar May 15th
Cannastocks2019 Live-Stream Investor Conference & Webinar May 15th
- GlobeNewswire•2 months ago
AXIM® Biotechnologies to Present at Cannastocks 2019 Q1 Conference
AXIM® Biotechnologies, Inc. (AXIM) (“AXIM® Biotech”, “Axim”, or the “Company”), a world leader in cannabinoid research and development, today announced that the Company will be attending and presenting at Cannastocks 2019 Q1 Conference, taking place in New York on May 15, 2019. AXIM’s Chief Executive Officer John W. Huemoeller II will bring his expertise to this year’s event, presenting on the Company’s updated business strategy, proprietary controlled-release technology and patent on all chewing gum containing cannabinoids, including the Company’s patented flagship chewing gum products.
- PR Newswire•2 months ago
Medical Marijuana, Inc. Major Investment Company Axim® Biotechnologies Files New U.S. Provisional Patent for Cannabis Gum as a Treatment for Migraine Symptoms
NEW YORK , May 14, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States , today announced that the Company's major investment ...
- InvestorPlace•3 months ago
7 Marijuana Stocks That Are Bleeding Cash
You may find it surprising, but the Post Office, the Atlanta Hawks and these seven marijuana stocks all have something in common. At first glance, you may think they have nothing to do with each other. After all, the Post Office is run by the government, the Atlanta Hawks are a professional basketball team and cannabis companies were established to profit off of the booming legal cannabis industry.But unfortunately, these very different organizations do in fact have something in common. And it just so happens that it is a very important thing. They are all losing money! None of them have made a profit in years!Obviously, the Post Office can continue to lose money forever because it's run by the governmental and the government can just raise taxes. And a professional sports team can continue to lose money as long as the owners are willing to sustain the losses.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut let's talk about the cannabis companies In the stock market, the idea is to invest in companies that are, or will be, profitable. This profitability will, in turn, lead to the share price appreciating. Financial theory, history and common sense all tell us that if a company doesn't make money it will eventually go out of business. Investors will see declining share prices and losses.Looking at the Cannabis Companies: You are probably familiar with the following companies if you trade or invest in the cannabis markets. They may have cool products and be in a cool industry, but if you are considering investing in them, it is important to understand that they are losing money. You may ask yourself, "how have they been able to lose money for a sustained period of time?"The answer is that they borrow money or issue stock and use these proceeds to cover their expenses. But eventually, the ability to do so will stop if they are never able to turn a profit. * 7 Strong Buy Stocks That Tick All the Boxes I am not saying that these companies will never earn money and that you can't profit by investing in their stocks. Some of them may eventually become great investments. My intent here is to express my belief that before making an investment in a company, one should consider if it is actually making money and what the future prospects of profitability are. In the long run, these dynamics will ultimately have a significant effect on the share price. Axim Biotechnologies (AXIM) Click to Enlarge Axim Biotechnologies (OTCMKTS:AXIM) makes a really cool product. It is a biotechnology company based in New York City. The company makes chewing gum that is infused with medicinal cannabis. This is used to treat pain, anxiety and other conditions. It can even be used to treat opioid addiction, which we all know is a terrible epidemic. I am not really sure how they do it because I'm a stock market guy, not a scientist, but I think it sounds like an awesome idea.But let's take a look at some numbers. Last year AXIM lost 12 cents per share. That means that for the year the company lost about $6.7 million. Unfortunately, losing money is nothing new to this company. In 2017 they lost $4.2 million, in 2016 the loss was $7.3 million, and it 2015 it was just over $10 million.Not surprisingly, the stock has not acted well. It is currently trading around the $1.50 level. As you can see on the chart, over the past year it has lost about 70% of its value. Maybe someday one of the company's product will be a huge success and it will become profitable, but over the past few years, it has certainly been a disappointment to shareholders. Americann (ACAN) Click to Enlarge Americann, Inc. (OTCMKTS:ACAN) is next on the list. Like many other cannabis companies, they are based in Denver. This company develops medical cannabis cultivation and processing properties. In other words, they build greenhouses. The greenhouses they build aren't like the kind my grandfather had in his garden. These are big-time greenhouses that are used for largescale industrial growing. They have built and developed over one million square feet of growing area.Americann has been involved with some enormous projects. Some of the projects include the Denver Medical Cannabis Center, the Massachusetts Medical Cannabis Center and the Illinois Medical Cannabis Center. The company is also committed to sustainability and uses clean energy from solar and geothermal sources. * 7 Stocks to Buy From the T. Rowe Price Health Sciences Fund Apparently, the Cannabis greenhouse business isn't very profitable -- at least in the way that Americann does it. Last year they lost $4.4 million which equates to a loss of 22 cents per share. This is more than they lost in the prior few years. In 2017 the loss was $2.7 million, in 2016 it was $2.2 million, and in 2015 the loss was $1.7 million. Maybe one day the company will be profitable but, as for now, they seem to be headed in the wrong direction. General Cannabis Corp. (CANN) Click to Enlarge General Cannabis Corp. (OTCMKTS:CANN) is a holding company that is based in Denver. They have four different segments -- security, operations, consumer goods and investments.The security segment provides different types of services to cannabis growers and retails stores. These services include video surveillance, transporting cash and providing security professionals. Consulting services to the cannabis industry that include obtaining licenses, compliance, logistics, retail operations and facility services are offered by the operations segment. The consumer goods segment includes developing relationships with apparel retailers and distributors. The investments segment provides loans and financing to companies within the cannabis industry.General cannabis is clearly an organization that is involved in many things. Maybe it is involved in too many things. Have you ever heard the expression "jack of all trades and master of none?" I think that could apply here. This company hasn't earned any money in years. Last year it lost almost $17 million, or 49 cents per share. The prior year's losses were less than half of that. In 2017, the loss was just over $8 million. In 2016, General cannabis lost just over $10 million and, in 2015, the loss was almost $9 million. If you're keeping track, this company has lost a total of $44 million in the past four years. Cannabis Sativa (CBDS) Click to Enlarge Cannabis Sativa, Inc. (OTCMKTS:CBDS) is next up on the list of losers. After looking at the company website for a while, I couldn't even figure out just what they actually do. I think it has something to do with providing services to cannabis dispensaries. Here is the description from MarketWatch:"Cannabis Sativa, Inc. engages in the research, development, acquisition and licensing of specialized natural cannabis related products, including cannabis formulas, edibles, topicals, strains, recipes and delivery systems. The company was founded on November 5, 2005 and is headquartered in Mesquite, NV."This company seems very mysterious to me. According to MarketWatch, there is only one employee despite having revenues that were over $500 million. One of the things that I noticed when I was looking at the financials is that the Quick Ratio is only 0.25 while the average Quick Ratio for the industry is 2.67.The Quick Ratio is the company's cash and short-term securities divided by the current liabilities. Current typically means one year or less. In other words, Cannabis Sativa only has 25 cents for each dollar of debt that they have, while the industry average is to have $2.61 for each $1 of debt. With a ratio like that, it isn't surprising that they are losing money. * 7 Energy Stocks to Buy to Light Up Your Portfolio The losses were $4.1 million in 2018, $7.6 million in 2017, $3.1 million in 2016, and $9.4 million in 2015. Tilray (TLRY) Click to Enlarge Tilray Inc. (NASDAQ:TLRY) hasn't been a publicly traded company for that long. The initial public offering was last summer. This company has the distinction of being the first publicly traded cannabis company to list on the Nasdaq. Their business model is very understandable. They engage in research, cultivation, production, and distribution of cannabis and cannabinoids. Products include dried cannabis and cannabis extracts. In other words, they grow and sell weed.Like the others, this company is losing money as well. I have heard that the cannabis markets are glutted and that the price of cannabis has fallen dramatically since its legalization. Many cannabis farmers are losing a lot of money. Maybe that is why Tilray is losing money as well.Tilray went public last year, but they have disclosed financial information going back further. If you think about it, it is kind of amazing that a company that loses money could go public. This was a common occurrence back in the dot-com era. The company has a market capitalization of around $5 billion despite the fact that they lost $67 million last year. In 2017, they lost about $8 million and had a similar size loss in 2016. 22nd Century Group (XXII) Click to Enlarge 22nd Century Group, Inc. (OTCMKTS:XXII) is based in Clarence, New York. It is a biotech company. They research and develop technologies that will allow the increase or decrease of the levels of nicotine and nicotinic alkaloids in tobacco plants and the levels of cannabinoids in cannabis plants. My guess is that there will be greater demand for increasing than decreasing. This is done through genetic engineering and plant breeding. Sounds like pretty neat stuff.But don't let their cool name and cool stock symbol fool you. They are losing money. Last year the loss was $10.4 million. That is a loss of 8 cents per share. In 2017, the annual loss was close to $17 million. The loss in 2016 was just over $15 million and the loss in 2015 was just over $14 million. * 7 Stocks Worth Buying When They're Down Maybe this company will turn around one day and become successful, but the current shareholders must be disappointed. The valuation has fallen by about one-third since December as the price per share has fallen from $3 to $2 while the broader equity markets have been booming since then. The Supreme Cannabis Co (SPRWF) Click to Enlarge The Supreme Cannabis Co, Inc. (OTCMKTS:SPRWF) is last on the list. Obviously, there are many other cannabis companies that are losing money out there, but today I just wanted to focus on these seven because they seem to be popular recently. Supreme has a similar business model as Tilray. The company grows and sells cannabis, although the product may be a little different because they say it is '"sun-grown." I suppose this is in contrast to being grown with artificial light. Supreme does this through their wholly owned subsidiary 7ACRES.Perhaps The Supreme Cannabis Company should consider changing their name to "The Subprime Cannabis Company" because it is losing money. It has seen the price of its stock fall by about 20% since September. Last year the company lost around $7.3 million. Losses in 2017 were more than twice that at $15.3 million. The loss in 2016 was $4.4 million and the loss in 2015 was about $5.7 million. Maybe the future will be better, but my guess is that The Supreme Cannabis Company's shareholders are supremely disappointed.As of this writing, Mark Putrino did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Energy Stocks to Buy to Light Up Your Portfolio * 10 Vice Stocks to Spice Up Your Portfolio * 7 of the Best ETFs to Buy for a Slowing Economy Compare Brokers The post 7 Marijuana Stocks That Are Bleeding Cash appeared first on InvestorPlace.
- Motley Fool•3 months ago
Don't Be Fooled by This Marijuana Penny Stock -- It's Bad News
Dig beneath its rapid sales growth, and you'll find good reason why this pot stock is down 19% since the year began.
- GlobeNewswire•3 months ago
AXIM® Biotechnologies, Inc. Nutraceutical Division Receives Purchase Order for 50,000 Boxes of the Company’s Proprietary CBD-Based Chewing Gum
NEW YORK, April 23, 2019 -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC: AXIM), a world leader in cannabinoid research and development, today.
- ACCESSWIRE•3 months ago
CBD Company to Research Now
HENDERSON, NV / ACCESSWIRE / April 16, 2019 / CBD is becoming a household name in the US. In a recent survey conducted with the Harris Poll, Quartz asked over 2,000 Americans about their use and perceptions ...
- GlobeNewswire•3 months ago
AXIM® Biotechnologies, Inc. Announces Attendance and Presentation by Chief Technology Officer Lekhram Changoer at Kannaway® “Believe” National Convention
NEW YORK, April 12, 2019 -- AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (OTC: AXIM), a world leader in cannabinoid research and development, today.
- PR Newswire•3 months ago
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Enters Services Agreement with CRO to Begin Clinical Studies on Dronabinol and CBD Chewing Gums
SAN DIEGO , April 10, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States , announced that its investment company AXIM® Biotechnologies ...
- GlobeNewswire•3 months ago
AXIM® Biotech Enters Services Agreement With CRO to Begin Clinical Studies On Dronabinol and CBD Chewing Gums
AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (AXIM), a world leader in cannabinoid research and development, today announced that it has entered into a Services Agreement with contract research organization (“CRO”) QPS Netherlands BV, a global leader in contract research, to begin separate bio comparison studies with its two leading drug candidates, MedChew® with dronabinol and CanChew® Rx. The CRO will conduct a two open label single dose studies (varying chew duration and concentration) followed by a double-blind, randomized, multiple dose study to test the bioavailability of dronabinol in MedChew®. MedChew® formulated with dronabinol is intended for treatment of chemotherapy-induced nausea and vomiting in cancer and AIDS patients.
- GlobeNewswire•4 months ago
AXIM® Biotechnologies, Inc. Appoints Mauricio Javier Gatto-Bellora to Company’s Board of Directors
AXIM® Biotechnologies, Inc. (“AXIM”) (“the Company”) (“AXIM® Biotech”) (AXIM), a world leader in cannabinoid research and development, today announced the appointment of Mauricio Javier Gatto-Bellora to the Company’s Board of Directors. Gatto-Bellora has more than three decades of experience in the pharmaceutical, biochemistry and cosmetics industries throughout the world with a specialty in strategizing and implementing plans for international success. Gatto-Bellora was also the President, CEO and Chairman of the Board of MonaVie, selling the company’s nutritional products in 46 countries.
- Market Exclusive•4 months ago
AXIM Biotechnologies Gets U.S. Patent for CBD Cream to Treat Atopic Dermatitis
Medical Marijuana (OTC: MJNA) reported that its portfolio company AXIM Biotechnologies (OTCQB: AXIM) has been granted a patent by the United States Patent and Trademark Office (USPTO) for a method to treat atopic dermatitis using cannabinoids. The USPTO has issued a notice of allowance for the patent to the company for a method to treat […]The post AXIM Biotechnologies Gets U.S. Patent for CBD Cream to Treat Atopic Dermatitis appeared first on Market Exclusive.
- Benzinga•4 months ago
AXIM Biotechnologies Receives Patent For CBD Cream For Eczema
AXIM Biotechnologies Inc. (OTC: AXIM), a cannabinoid research and development company, has been issued a Notice of Allowance for a patent from the U.S. Patent and Trademark Office for a topical cream containing cannabinoids for the treatment of atopic dermatitis (eczema). The Notice of Allowance was granted for a patent application Axim filed Aug. 21, 2018. The cream includes two cannabinoids: cannabidiol (CBD) and cannabigerol (CBG), which were proven to provide anti-inflammatory and pain relief benefits.
- PR Newswire•4 months ago
Medical Marijuana, Inc. Portfolio Company AXIM® Biotechnologies Receives New U.S. Patent Issuance for Topical Cream Containing Cannabinoids
SAN DIEGO , March 27, 2019 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States , announced that its portfolio company AXIM® Biotechnologies ...
